The volume of data a pharma firm receives in the age of social media, AI (Artificial Intelligence), and ubiquitous mobility is unparalleled. Combined with a significant shift in the underlying technology stack, increasing regulatory reporting requirements, and shorter turnaround times, there is a perfect storm occurring in the world of pharmacovigilance (PV).

Our research establishes how these changes not only help reimagine PV but also unlock meaningful value through a 20 - 30% cost reduction in PV spend for a large pharma firm.

Please share your details to read about the top three innovation triggers in PV that large pharma firms should know about.